Skip to content
value.today

Indaptus Therapeutics, Inc.

INDP
$513 Mmarket cap on Oct 30, 2026+3320.2% since Jan 2024
Compare
World rank
#12,431
Revenue
—
For year ending December-2025
Net income
$-21 M
SEC filing
Employees
—

Indaptus Therapeutics, Inc. in brief

Indaptus Therapeutics, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $513 M on 30 October 2026, which makes it the 12,431st largest listed company in the world and the 2,510th largest in the USA on this site. Junyi Dai is its chief executive. Its shares trade under the symbol INDP (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Indaptus Therapeutics, Inc.

We are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity in preclinical models, including durable anti-tumor response synergy observed with each of four different classes of existing agents, including NSAIDs, checkpoint therapy, targeted antibody therapy and low-dose chemotherapy. Tumor eradication by our technology was associated with induction of both innate and adaptive immunological memory and, importantly, did not require provision of or targeting a tumor antigen in preclinical models. In 2023, we initiated a Phase 1 clinical trial with our lead clinical candidate, Decoy20, in patients with advanced solid tumors where currently approved therapies have failed. In May 2025, we decided to conclude enrollment in the dosing of Decoy20 as a monotherapy and focus on the combination study of Decoy20 with BeOne’s anti-PD-1 antibody, Tislelizumab for the treatment of participants with advanced solid tumors, or the Combination Study. As of the date of this Annual Report on Form 10-K, we have discontinued further enrollment in the Combination Study and there are no participants remaining in the study. We do not have any current plans to initiate a new clinical trial.

From the company's annual report filed with the US SEC: read the report

Indaptus Therapeutics, Inc. timeline

2 events, 2021
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed Indaptus Therapeutics, Inc.
    Formerly Intec Parent Inc..

Events of Indaptus Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$139 M$277 M$416 M$554 M2023202420252026

World rank over time

▲ up 14,186 places since 2022
2022-01-07: #26645#26,64520222022-12-25: #26645#26,64520222024-01-05: #29824#29,82420242026-03-08: #13255#13,25520262026-08-01: #16345#16,34520262026-10-14: #13988#13,98820262026-10-30: #12459#12,4592026

Rank in USA: #4,954 (Jan 2022) · #5,472 (Dec 2022) · #4,432 (Jan 2024) · #2,455 (Mar 2026) · #3,261 (Aug 2026) · #2,730 (Oct 2026) · #2,513 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
162.9×
Free cash flow yield
-2.2%
Net margin
—
Operating margin
—
Return on equity
-661.9%
Liabilities / assets
66.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-4M—FY20Fiscal year ending Dec 2021: revenue —, net income $-8M—FY21Fiscal year ending Dec 2022: revenue —, net income $-14M—FY22Fiscal year ending Dec 2023: revenue —, net income $-15M—FY23Fiscal year ending Dec 2024: revenue —, net income $-15M—FY24Fiscal year ending Dec 2025: revenue —, net income $-21M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-20M$-21M—
Dec 2024——$-15M$-15M—
Dec 2023——$-16M$-15M—
Dec 2022——$-15M$-14M—
Dec 2021——$-8M$-8M—
Dec 2020——$-4M$-4M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-15M——$-21.58—
Dec 2024$-12M——$-44.96—
Dec 2023$-13M——$-1.83—
Dec 2022$-13M——$-1.73—
Dec 2021$-11M$0M$-11M$-1.89—
Dec 2020$-3M——$-1.84—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue —, net income $-5M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-8M—Dec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue —, net income $-1M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Indaptus Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-20 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$9 M
Total liabilities
$6 M
Total equity
$3 M

As of December-2025

Top 21 institutional investors in Indaptus Therapeutics, Inc.#

As of Sep 30, 2026
21 institutions held 946,551 shares (about 0.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 21 largest institutional investors in Indaptus Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Geode Capital Management, LLC195,620+139,150 (+246.41%)0.15%$0 MNov 6, 2026
2Vanguard Capital Management LLC135,978+102,326 (+304.07%)0.10%$0 MNov 13, 2026
3Jane Street Group, LLC86,484+32,673 (+60.72%)0.06%$0 MNov 12, 2026
4UBS Group AG83,363+82,885 (+17339.96%)0.06%$0 MNov 10, 2026
5Marshall Wace, LLP77,847New0.06%$0 MNov 13, 2026
6Millennium Management LLC72,073+60,487 (+522.07%)0.05%$0 MNov 16, 2026
7Vanguard Fiduciary Trust Co65,315+51,348 (+367.64%)0.05%$0 MNov 13, 2026
8State Street Corp63,866New0.05%$0 MNov 12, 2026
9Virtu Financial LLC34,659New0.03%$0 MNov 17, 2026
10Jump Financial, LLC27,662New0.02%$0 MNov 13, 2026
11Northern Trust Corp27,227New0.02%$0 MNov 16, 2026
12ExodusPoint Capital Management, LP19,884New0.01%$0 MNov 16, 2026
13Qube Research & Technologies Ltd14,688New0.01%$0 MNov 13, 2026
14Goldman Sachs Group Inc14,143New0.01%$0 MNov 16, 2026
15Barclays PLC13,723New0.01%$0 MNov 6, 2026
16Balyasny Asset Management L.P.12,708New0.01%$0 MNov 16, 2026
17Morgan Stanley1,263-7,673 (-85.87%)0.00%$0 MNov 13, 2026
18Jpmorgan Chase & Co28New0.00%$0 MNov 12, 2026
19SBI Securities Co., Ltd.170 (0.00%)0.00%$0 MOct 22, 2026
20Caitong International Asset Management Co., Ltd2New0.00%$0 MOct 29, 2026
21Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Indaptus Therapeutics, Inc.#

4 funds hold shares worth $0 M (about 0.0% of the company). Since their previous reports 3 added shares and 0 sold, buying $0 M net.
Mutual funds holding Indaptus Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC17,640$0 M0.01%<0.01%+118%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.9,142$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC3,929$0 M<0.01%<0.01%+676%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC462$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Indaptus Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
7
since
Indaptus Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Avraham Ben-TzviDirectorGrant or award+25,000——25,100Form 4
filed Nir SassiChief Financial OfficerGrant or award+26,758$2.030$54 K26,758Form 4
filed Jeffrey A. MecklerCo-Chief Executive Officer, Director, 10% ownerGrant or award+216,617$2.030$440 K229,929Form 4
filed Walt Addison LinscottChief Operating OfficerGrant or award+54,421$2.030$110 K54,426Form 4
filed Michael James NewmanCSO and Director, DirectorGrant or award+52,204$2.030$106 K101,074Form 4
filed Jeffrey A. MecklerChief Executive Officer, DirectorGrant or award+6,068$8.300$50 K13,312Form 4
filed Jeffrey A. MecklerCEO and Director, DirectorGrant or award+42,553$1.180$50 K202,859Form 4
filed Jeffrey A. MecklerCEO and Director, DirectorGrant or award+84,932$1.830$155 K160,306Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Indaptus Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.1 M
52.6% of shares · 3.96 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-06-04 16:47 UTC, code LUDP, resumed 16:57 UTC
  • 2025-10-07 15:32 UTC, code LUDP, resumed 15:37 UTC
  • 2025-10-07 15:04 UTC, code LUDP, resumed 15:09 UTC
  • 2025-10-07 14:11 UTC, code LUDP, resumed 14:16 UTC
  • 2025-10-07 14:00 UTC, code LUDP, resumed 14:10 UTC

Fails to deliver

  • : 162 shares at $3.34
  • : 1,094 shares at $3.33
  • : 12,077 shares at $3.16
  • : 444 shares at $2.99
  • : 1,883 shares at $3.16

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Indaptus Therapeutics, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median162.9×Price to book 162.9× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-2.2%Free cash flow is -2.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-21.58 vs -44.96Diluted EPS -21.58 in fiscal 2025 against -44.96 the year before (report's currency).
    • ✗Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$4 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-588.1%-588.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.51 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year189.2%Diluted shares up 189.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Indaptus Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Indaptus Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development9,3417,2517,6226,3252,5232,655
General and administrative10,4938,1158,7578,5865,206944
Operating expenses19,83415,36616,37814,9117,7293,599
Operating income−19,834−15,366−16,378−14,911−7,729−3,599
Other non-operating income (expense)—3449555881815
Income before tax−20,847−15,020————
Income tax1.71.72.50.01.70.8
Net income attributable to shareholders−20,849−15,022−15,423−14,323−7,711−3,584
Earnings per share, basic-21.58-44.96r-1.83-1.73-1.89-1.84
Earnings per share, diluted-21.58-44.96r-1.83-1.73-1.89-1.84
Shares, weighted average (basic)1.00.3r8.48.34.1—
Shares, weighted average (diluted)1.00.3r8.48.34.11.9
Balance sheet
Cash and cash equivalents8,5085,78713,3629,62739,1321,637r
Short-term investments———16,806——
Other current assets8038326338111,10795r
Current assets9,3106,61813,99527,24440,3871,732r
Property, plant and equipment——0.72.03.81.3r
Right-of-use (leased) assets—8217379169817
Non-current assets—72092982018946r
Total assets9,3107,33914,92428,06440,5771,778r
Accounts payable5448708061,3782,540r156r
Current liabilities6,1593,3942,7743,4334,6042,015r
Lease liabilities (non-current)——73—73338
Non-current liabilities——73—731,029
Total liabilities6,1593,3942,8473,4334,6772,015r
Retained earnings−81,288−60,439−45,417−29,994−15,671−7,960r
Shareholders' equity3,1523,94512,07624,63035,900−238r
Total liabilities and equity9,3107,33914,92428,06440,5771,778r
Shares outstanding2.20.4r8.48.48.31.9r
Cash-flow statement
Share-based compensation1,3582,3062,9662,9571,510140
Cash from operating activities−14,823−12,323−13,405−13,078−11,291−3,325
Capital expenditure————−3.9—
Cash from investing activities——17,141−16,427448—
Shares issued6,3975,511————
Cash from financing activities17,5444,748——48,3371,163
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Indaptus Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.2 M
Jeffrey A. Meckler
Other top executives, average
$1.8 M
the CEO earned 1.2× this
$100 invested is now
$12
Indaptus Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Jeffrey A. Meckler$2.2 M$2.1 M$1.8 M$12
2024Jeffrey A. Meckler$1.2 M$1.0 M$950 K$48
2023Jeffrey A. Meckler$1.0 M$1.1 M$744 K$121

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Indaptus Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Change in control 2 · Directors and officers 10 · Material agreement 9 · New debt 2 · Unregistered share sale 7 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 4 · Results announced 4

Indaptus Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Material agreementUnregistered share sale8-K
Material agreement8-K/A
Directors and officers8-K
Material agreement8-K
Shareholder voteResults announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K/A
Directors and officers8-K
Directors and officers8-K
Change in controlDirectors and officers8-K
Change in controlShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Directors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Unregistered share saleShareholder vote8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Indaptus Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$2 MPrivate placement after listing$2 to $10 million20optionsSEC
Jan 2025$2 MPrivate placement after listing$2 to $10 million16equity, optionsSEC
Jul 2021$30 MIssued in a merger or acquisition$10 to $50 million1optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Indaptus Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2021–2021
Latest
—
2021-08-12
Indaptus Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2021············—
Indaptus Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

Discuss Indaptus Therapeutics, Inc.#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Mutual funds: 4 funds hold $70,000automatic update · Jun 30, 2026

    4 mutual funds in 1 country hold shares of Indaptus Therapeutics, Inc. worth $70,000, about 0.0% of the company (funds' newest reports, up to 30 June 2026). Since their previous reports 3 funds added shares and 0 sold; on balance they bought $50,000. Share splits are not counted as trading.

How Indaptus Therapeutics, Inc. compares in Biotechnology

  • Market cap$513 M · higher than 59% of 726
  • Price / book162.9× · lower than 1% of 534
  • FCF yield-2.2% · higher than 80% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Indaptus Therapeutics, Inc.🇺🇸$513 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Indaptus Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Indaptus Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Indaptus Therapeutics, Inc.? Suggest a correction